Drug Trial Radar · NCT05308953
A Phase I Safety Study of NVG-291 in Healthy Adults
Last checked: Nov 19, 2026Latest source record: Jan 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
74
Actual
Start
May 6, 2021
Primary completion
Jun 4, 2023
Study completion Jul 3, 2023
Sponsor
- Lead sponsor
- NervGen PharmaIndustry
- Sponsor type
- Industry
- First posted
- Apr 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, triple-blind (subjects, Investigators, and Sponsor blinded), placebo-controlled Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) study to evaluate the safety and tolerability of NVG-291 administered by subcutaneous injection daily in healthy female participants. The trial is split into three parts, starting with Part 1 (SAD), then Part 2 (MAD - post-menopausal Females), and finally Part 3 (MAD - males and premenopausal females). In Part 1 (SAD), participants receive 1 dose on 1 day only and in Parts 2 and 3, participants receive 1 dose every day for 14 days.
Conditions
- Spinal Cord Injury
Interventions
NVG-291Drug
NVG-291 is a drug injected under the skin (subcutaneous).
PlaceboOther
Salt water is being used as a placebo and will be injected under the skin (subcutaneous).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: Assessed through 7 days following the last dose of study drug
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Networks
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.